Member Info for Bebeto

From 15th November RNS

The Board expects that the impact of these adjustments will now mean that EBIT for HY19 will represent a loss of not less than £12m.... The Board believes that the Group's underlying operations have been trading profitably in the second half and the Board now expects EBIT for the full year of no more than £2m.

The loans has to be repaid no later than August 2021. The idea with these loans is that company will be able to use the money to sort out their balance sheet and then have more than enough to pay all the loan off when the time comes.

The Dbay deal values the company MCAP at £107M or 28.25p per share.

They are in it for the long haul (pun intended) DBAY is a value investor. It is sector agnostic and aims to support companies in which it makes long term investments to develop clear growth opportunities with a particular emphasis on creating long term value by working alongside management teams

Just to be clear what a PIK loan is as there seems to be some misunderstanding between investors here.
A "payment-in-kind" (PIK) note (or loan) is a way for companies to borrow money. When issuing a bond, a company typically borrows a fixed amount of money, for a fixed period of time, and pays a fixed amount of interest every year. With a PIK note, rather than pay interest each year, the interest is rolled up (capitalised) and added to the principal (hence the name, payment in kind you are being asked to forgo annual interest payments in exchange for a higher overall payment at maturity).

2.25499% of company in one trade !

No chance of a placement at this time, the shareprice is far too low and also it's too oversold.

Yeah £51.42k worth of sells isn't going to change anything anyway.

The RSI has moved from 6 to 12 on the daily, so this share is still massively oversold and indicates to me that the big selling pressure is definitely weaker now.!

Not delayed as they are time stamped correctly, there's a cancelled trade between the last buy and the two sells, which probably caused confusion to people.

They are sells, last aftermarket buy was at 11.588.

Yesterday's retrace should have been around 23% but the buying pressure was too strong. Probably playing that out today, share looks strong to me as everyone knows it's undervalued & oversold.!

If you can read a chart you'll see it bounced off resistance, even though today's ceiling will be another day's floor.!

Shareprice increased after £404k 5.3M shares sell this morning at 08.53.

Seller out.!

Margin Of Safety (MOS or Safety Margin)

Is the difference between the intrinsic value of a stock and it's market price.

There's still over another 200% rise in the tank here.!

Where's the shame in calling an old share wrong?

Now we have some figures to chew over , everyone can see the shareprice is already 6.5 times too high.!

So a company with £9M MCAP has sales of £3M for new product and the MCAP has been hyped up to £78M ... There's a long way to go here IMO

FDA fast tracked approval won't be before mid-March going by the fast tracked CDC test kit.

Way too volatile for anyone to short, what you're seeing is profits taking and stop losses

In the meantime more and more investors are going underwater, which would kill any significant rise as shown twice here already.

Cure is here and by the chinese https://vuuzletvph.com/favilavir-first-covid-19-drug-approved/ they started production yesterday The government of Taizhou in Zhejiang province declared Sunday that Favilavir, formerly known as Fapilavir, an antiviral that has shown efficacy in the treatment of the novel coronavirus (COVID-19), has been approved to be sold in the market. It is the first antiviral drug approved by the National Medical Products Administration for marketing since the outbreak happened. The drug is expected to play a vital role in preventing and treating the pandemic. The government said on its verified WeChat page that it was developed by Zhejiang Hisun Pharmaceutical Company. On Saturday, the Ministry of Science and Technology said that Favilavir is one out of three drugs which have shown significant effectiveness in drug trials to fight the COVID-19. On Sunday, the first antiviral drug was set for production

Cure is here and by the chinese https://vuuzletvph.com/favilavir-first-covid-19-drug-approved/ they started production yesterday The government of Taizhou in Zhejiang province declared Sunday that Favilavir, formerly known as Fapilavir, an antiviral that has shown efficacy in the treatment of the novel coronavirus (COVID-19), has been approved to be sold in the market. It is the first antiviral drug approved by the National Medical Products Administration for marketing since the outbreak happened. The drug is expected to play a vital role in preventing and treating the pandemic. The government said on its verified WeChat page that it was developed by Zhejiang Hisun Pharmaceutical Company. On Saturday, the Ministry of Science and Technology said that Favilavir is one out of three drugs which have shown significant effectiveness in drug trials to fight the COVID-19. On Sunday, the first antiviral drug was set for production